Mycoses

Papers
(The TQCC of Mycoses is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
COVID‐19‐associated mucormycosis: An updated systematic review of literature187
ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countries143
Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity141
The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis134
Increased incidence of candidemia in a tertiary care hospital with the COVID‐19 pandemic122
Mucormycosis and COVID‐19: An epidemic within a pandemic in India120
Mucormycosis in patients with COVID‐19: A cross‐sectional descriptive multicentre study from Iran103
Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis: A systematic review and meta‐analysis78
Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k)76
Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients72
Prevalence of opportunistic invasive aspergillosis in COVID‐19 patients with severe pneumonia58
Epidemiology and Mycology of Candidaemia in non‐oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non‐COVID‐19 and COV53
Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches52
COVID‐19–associated pulmonary aspergillosis: a prospective single‐center dual case series47
Axillary Digital Thermometers uplifted a multidrug‐susceptible Candidaauris outbreak among COVID‐19 patients in Brazil45
Results from a national survey on COVID‐19‐associated mucormycosis in Germany: 13 patients from six tertiary hospitals42
Accuracy of galactomannan testing on tracheal aspirates in COVID‐19‐associated pulmonary aspergillosis42
Invasive dermatophyte infection: A systematic review41
Increased incidence of rhino‐orbital mucormycosis in an educational therapeutic hospital during the COVID‐19 pandemic in western Iran: An observational study39
Let's talk about sex characteristics—As a risk factor for invasive fungal diseases39
Global prevalence and subgroup analyses of coronavirus disease (COVID‐19) associated Candida auris infections (CACa): A systematic review and meta‐analysis38
Gut mycobiome: The probable determinative role of fungi in IBD patients35
Epidemiology of invasive fungal disease in haematologic patients34
Is there an association between zinc and COVID‐19–associated mucormycosis? Results of an experimental and clinical study34
Proven COVID‐19—associated pulmonary aspergillosis in patients with severe respiratory failure32
Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiary‐care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibil31
Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID‐19) patients: A systematic review30
Evaluation of DermaGenius® resistance real‐time polymerase chain reaction for rapid detection of terbinafine‐resistant Trichophyton species29
Talaromyces marneffei infection in non–HIV‐infected patients in mainland China29
Mortality in critically ill patients with coronavirus disease 2019‐associated pulmonary aspergillosis: A systematic review and meta‐analysis29
Estimation of the burden of tinea capitis among children in Africa28
Systematic screening for COVID‐19 associated invasive aspergillosis in ICU patients by culture and PCR on tracheal aspirate27
Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis27
Serum iron indices in COVID‐19‐associated mucormycosis: A case–control study27
Risk factors for candidaemia: A prospective multi‐centre case‐control study27
Superficial mycoses, a matter of concern: Global and Indian scenario‐an updated analysis25
Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: A systematic review and meta‐analysis25
Point mutations in the squalene epoxidase erg1 and sterol 14‐α demethylase erg11 gene of T indotineae isolates indicate that the resistant mutant strains evolved independently25
COVID‐19‐associated pulmonary aspergillosis (CAPA): Risk factors and development of a predictive score for critically ill COVID‐19 patients25
Species distribution, azole resistance and related molecular mechanisms in invasive Candida parapsilosis complex isolates: Increase in fluconazole resistance in 21 years25
Host immune responses in dermatophytes infection23
Tinea capitis et barbae caused by Trichophyton tonsurans: A retrospective cohort study of an infection chain after shavings in barber shops23
Azole resistance in Aspergillus fumigatus. The first 2‐year's Data from the Danish National Surveillance Study, 2018–202023
South Asian (Clade I) Candida auris meningitis in a paediatric patient in Iran with a review of the literature22
The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta‐analysis22
Trichosporon asahii superinfections in critically ill COVID‐19 patients overexposed to antimicrobials and corticosteroids22
In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes21
Predicting a therapeutic cut‐off serum level of itraconazole in recalcitrant tinea corporis and cruris—A prospective trial21
Collateral consequences of agricultural fungicides on pathogenic yeasts: A One Health perspective to tackle azole resistance20
A review of significance of Aspergillus detection in airways of ICU COVID‐19 patients20
Tinea pedis—An embarrassing problem for health and beauty—A narrative review19
Current situation of endemic mycosis in the Americas and the Caribbean: Proceedings of the first international meeting on endemic mycoses of the Americas (IMEMA)19
Expert recommendations for prevention and management of Candida auris transmission19
Disseminated cryptococcosis and anti‐granulocyte‐macrophage colony‐stimulating factor autoantibodies: An underappreciated association19
Successful control of Candida auris transmission in a German COVID‐19 intensive care unit19
Inflammasome‐mediated Inflammation by Malassezia in human keratinocytes: A comparative analysis with different strains18
New weapons to fight a new enemy: A systematic review of drug combinations against the drug‐resistant fungus Candida auris18
Anti‐fungal agents in the treatment of chronic pulmonary aspergillosis: Systematic review and a network meta‐analysis18
Glucan rich nutrition does not increase gut translocation of beta‐glucan18
Cryptococcosis among hospitalised patients with COVID‐19: A multicentre research network study17
A multicentric clinical and epidemiological study of chronic and recurrent dermatophytosis in India17
Role of flexible bronchoscopy in the diagnosis of invasive fungal infections17
Serum Lateral Flow assay with digital reader for the diagnosis of invasive pulmonary aspergillosis: A two‐centre mixed cohort study17
Mucormycosis at a tertiary‐care center in Mexico. A 35‐year retrospective study of 214 cases17
Report of terbinafine resistantTrichophytonspp. in Italy: Clinical presentations, molecular identification, antifungal susceptibility testing and mutations in the squalene epoxidase gene17
Clinical features, diagnosis and treatment outcome of fungal endocarditis: A systematic review of reported cases17
A screening study for COVID‐19‐associated pulmonary aspergillosis in critically ill patients during the third wave of the pandemic17
Molecular identification and antifungal susceptibility among clinical isolates of dermatophytes in Shiraz, Iran (2017‐2019)17
Proven Aspergillus flavus pulmonary aspergillosis in a COVID‐19 patient: A case report and review of the literature16
How does temperature trigger biofilm adhesion and growth in Candida albicans and two non‐Candida albicans Candida species?16
Complementary effect of mechanism of multidrug resistance in Trichophyton mentagrophytes isolated from human dermatophytoses of animal origin16
Invasive fungal infections in acute and chronic liver impairment: A systematic review16
Malignant Transformation and Treatment Recommendations of Chronic Hyperplastic Candidiasis—A Six‐year Retrospective Cohort Study16
COVID‐19–associated mucormycosis, diabetes and steroid therapy: Experience in a single centre in Western Mexico16
Invasive aspergillosis due to Aspergillus cryptic species: A prospective multicentre study16
Deep learning‐based diagnosis models for onychomycosis in dermoscopy15
Dysbiosis of skin mycobiome in atopic dermatitis15
Aspergillus‐PCR in bronchoalveolar lavage ‐ diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patients15
Performance evaluation of fungal DNA PCR amplification from formalin‐fixed paraffin‐embedded tissue for diagnosis: Experience of a tertiary reference laboratory15
The design and application of an automated microscope developed based on deep learning for fungal detection in dermatology15
Invasive aspergillosis in solid organ transplantation: Diagnostic challenges and differences in outcome in a Spanish national cohort (Diaspersot study)15
Multimodal analysis of the COVID‐19‐associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical and environmental risk factors15
Antifungal susceptibility testing of dermatophytes: Development and evaluation of an optimised broth microdilution method15
Implementation of rapid diagnostics assays for detection of histoplasmosis and cryptococcosis in central american people living with HIV14
Serum Aspergillus galactomannan lateral flow assay for the diagnosis of invasive aspergillosis: A single‐centre study14
Alternative treatment of fungal infections: Synergy with non‐antifungal agents14
Drug repurposing against Candida auris: A systematic review14
Epidemiology, clinical presentation and management of COVID‐19 associated mucormycosis: A single centre experience from Pune, Western India14
Comparative analysis of galactomannan lateral flow assay, galactomannan enzyme immunoassay and BAL culture for diagnosis of COVID‐19‐associated pulmonary aspergillosis14
Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID‐19–associated mucormycosis in a real‐life setting14
Molecular‐based assessment of diversity and population structure of Sporothrix spp. clinical isolates from Espírito Santo‐Brazil14
Identification of Candida auris and related species by multiplex PCR based on unique GPI protein‐encoding genes13
Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open‐label randomized controlled trial13
Frequency of occurrence, seasonal variation and antifungal susceptibility of opportunistic Mucorales isolated from hospital soils in Iran13
Incidence and risk factors for COVID‐19 associated candidemia (CAC) in ICU patients13
Serious fungal disease incidence and prevalence in Indonesia13
Itraconazole resistance of Trichophyton rubrum mediated by the ABC transporter TruMDR213
Epidemiology and outcomes of allergic bronchopulmonary aspergillosis in the elderly13
Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda13
Global epidemiological burden of fungal infections in cirrhosis patients: A systematic review with meta‐analysis13
Validation and implementation of a commercial real‐time PCR assay for direct detection of Candida auris from surveillance samples13
Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta‐analysis12
Tinea capitis in children: A single‐institution retrospective review from 2011 to 201912
Epidemiology of dermatomycoses and onychomycoses in Ireland (2001–2020): A single‐institution review12
Sensitization to A fumigatus in subjects with non‐cystic fibrosis bronchiectasis12
Molecular identification and antifungal susceptibility profiles of Candida dubliniensis and Candida africana isolated from vulvovaginal candidiasis: A single‐centre experience in Iran12
New insights into development and mortality of COVID‐19‐associated pulmonary aspergillosis in a homogenous cohort of 1161 intensive care patients12
Diagnostic performance of real‐time polymerase chain reaction assay on blood for invasive aspergillosis and mucormycosis12
Serologic biomarkers in Candida and Aspergillus infections of the central nervous system: A comparison of galactomannan, mannan and β‐1,3‐D‐gucan testing from serum and cerebr12
A pseudo‐outbreak of Rhinocladiella similis in a bronchoscopy unit of a tertiary care teaching hospital in London, United Kingdom11
Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital11
Time and cost‐efficient identification of Trichophyton indotineae11
Emergence of Candida auris in intensive care units in Algeria11
Laboratory‐based surveillance of Candida auris in Colombia, 2016–202011
Five‐year surveillance study of clinical and environmental Triazole‐ResistantAspergillus fumigatus isolates in Iran11
Effects of oestrogen on vulvovaginal candidosis11
COVID‐19‐associated subacute invasive pulmonary aspergillosis11
Candida auris from colonisation to candidemia: A four‐year study11
Azole resistance in Aspergillus isolates by different types of patients and correlation with environment ‐ An Italian prospective multicentre study (ARiA study)11
Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole11
Whole genome sequencing analysis demonstrates therapy‐induced echinocandin resistance in Candida auris isolates10
Diagnostic accuracy of Aspergillus‐specific antibodies for chronic pulmonary aspergillosis: A systematic review and meta‐analysis10
Non‐dermatophyte fungi in onychomycosis—Epidemiology and consequences for clinical practice10
Direct examination, histopathology and fungal culture for the diagnosis of onychomycosis: A retrospective, comparative study on 2245 specimens10
Isolated tracheobronchial mucormycosis: Report of a case and systematic review of literature10
Genotyping and antifungal susceptibility testing of Sporothrix brasiliensis isolates from Southern Brazil10
Mucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes10
COVID‐19‐associated aspergillosis in a Brazilian referral centre: Diagnosis, risk factors and outcomes10
Concurrent diagnosis of sinus fungus ball and invasive fungal sinusitis: A retrospective case series10
Serious fungal diseases in Democratic Republic of Congo – Incidence and prevalence estimates10
COVID‐19‐associated pulmonary aspergillosis in ICU patients in a German reference centre: Phenotypic and molecular characterisation of Aspergillus fumigatus isolates10
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non‐fumigatus): A multicentre, non‐interventional regist10
Genetic differences between Japan and other countries in cyp51A polymorphisms of Aspergillus fumigatus10
Could cattle dung burning have contributed to the epidemic of COVID‐19‐associated mucormycosis in India? Results of an experimental aero‐mycological study10
Risk factors of severe blastomycosis and comparison of diagnosis and outcomes between immunocompetent and immunocompromised patients9
Immune reconstitution inflammatory syndrome in non‐HIV cryptococcal meningitis: Cross‐talk between pathogen and host9
Changing face of epidemiology of dermatophytoses in Chinese Mainland: A 30 years nationwide retrospective study from 1991 to 20209
A lateral flow assay for the immunodiagnosis of human cat‐transmitted sporotrichosis9
Clinical features and Outcomes of Cryptococcemia patients with and without HIV infection9
Increasing Incidence of mucormycosis in Spanish inpatients from 1997 to 20189
Endemic mycoses: Expansion of traditional geographic ranges and pitfalls in management9
Comparative diagnostic accuracy of immunoprecipitation versus immunoassay methods for detecting Aspergillus fumigatus‐specific IgG in allergic bronchopulmonary aspergillosis: A syste9
Clinical and epidemiological characteristics of tinea capitis in northern Taiwan during 2014‐2019: An unusual bimodal distribution of patients and comparison of paediatric and adult cases9
Real‐life applicability of the Euroarray dermatomycosis kit in the diagnosis of onychomycosis9
Identification of distinct immunophenotypes in chronic pulmonary aspergillosis using cluster analysis9
Molecular and MALDI‐ToF MS differentiation and antifungal susceptibility of prevalent clinical Fusarium species in China8
Epidemiological cut‐off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma8
Performance of existing clinical scores and laboratory tests for the diagnosis of invasive candidiasis in critically ill, nonneutropenic, adult patients: A systematic review with qualitative evidence 8
CATastrophe: Response to the challenges of zoonotic sporotrichosis in southern Brazil8
Activities of nine antifungal agents against Candida auris biofilms8
Diagnosis of allergic bronchopulmonary aspergillosis in patients with persistent allergic asthma using three different diagnostic algorithms8
Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents8
The accuracy and clinical impact of the morphological identification of Aspergillus species in the age of cryptic species: A single‐centre study8
Isavuconazole nonwildtype Aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously as8
Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic8
The use of combined PCR, fluorescence in situ hybridisation and immunohistochemical staining to diagnose mucormycosis from formalin‐fixed paraffin‐embedded tissues8
Aspergillus endocarditis in the recent years, report of cases of a multicentric national cohort and literature review8
Dihydroorotate dehydrogenase inhibitor olorofim has potent in vitro activity against Microascus/Scopulariopsis, Rasamsonia, Penicillium and Talaromyces species8
Incidence, predisposing conditions and outcomes of cutaneous mucormycosis: A national database study8
Antifungal activity of boric acid, triclosan and zinc oxide against different clinically relevant Candida species8
Multilocus sequence typing (MLST) analysis reveals many novel genotypes and a high level of genetic diversity in Candida tropicalis isolates from Italy and Africa8
Systematic review of neuroparacoccidioidomycosis: The contribution of neuroimaging8
Multilocus sequence typing of strains from the Cryptococcus gattii species complex from different continents7
Effect of glucocorticoids on the development of COVID‐19‐associated pulmonary aspergillosis: A meta‐analysis of 21 studies and 5174 patients7
Comparative genomics of opportunistic Phialophora species involved in divergent disease types7
As the virus sowed, the fungus reaped! A comparative analysis of the clinico‐epidemiological characteristics of rhino‐orbital mucormycosis before and during COVID‐19 pandemic7
Multicentre derivation and validation of a prognostic scoring system for mortality assessment in HIV‐infected patients with talaromycosis7
Paediatric cutaneous mucormycosis: A case report and review of the literature7
Vaginal microbiota in pregnant women with inflammatory rheumatic and inflammatory bowel disease: A matched case‐control study7
Treatment of the Candida subspecies Candida albicans and Candida parapsilosis with two far‐UVC sources to minimise mycoses in clinical practice7
Quality of life in women with chronic recurrent vulvovaginal candidosis: A sub‐analysis of the prospective multicentre phase IIb/III Prof‐001 study7
In vitro antifungal susceptibility patterns of Trichophytonbenhamiae complex isolates from diverse origin7
Characterisation of the nail microbiome in psoriatic and nonpsoriatic patients with onychomycosis7
The risk factor analysis and treatment experience in pneumocystis jirovecii pneumonia after kidney transplantation7
Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure–response analysis7
Candida spp. infective endocarditis: Characteristics and outcomes of twenty patients with a focus on injection drug use as a predisposing risk factor7
Fungaemia due to rare yeasts in paediatric intensive care units: A prospective study7
Evaluation of metagenomic next‐generation sequencing diagnosis for invasive pulmonary aspergillosis in immunocompromised and immunocompetent patients7
Risk factors and outcomes of deep tissue Candida invasion in neonates with invasive candidiasis7
Deep convolutional neural networks for onychomycosis detection using microscopic images with KOH examination7
Machine‐learning‐based virtual screening to repurpose drugs for treatment of Candida albicans infection7
Changing demographics and risk factors for cryptococcosis: A 12‐year review at a tertiary care centre7
0.049569129943848